Almac selected as preferred partner for EORTC clinical trials

By Melissa Fassbender contact

- Last updated on GMT

Almac selected as preferred partner for EORTC clinical trials

Related tags: Cancer

Almac Diagnostics will initiate sample profiling on current EORTC trials to further biomarker discovery and development.

Through the partnership, Almac Diagnostics will support molecular profiling of cancer patient samples collected by the European Organization for the Research and Treatment of Cancer (EORTC) and SPECTA (Screening Patients for Effective Clinical Trial Access).

"The ​SPECTA Program team require a partner to provide consistent, quality analysis of samples from their clinical trials​," Michael Sloan, VP Business Development, Almac Diagnostics, told Outsourcing-Pharma.com.

"They sought a partner who can provide a robust quality service and support the discovery, development and ultimately commercialization of biomarkers​."

Specifically, Almac Diagnostics will analyze patterns of genomic variation within patient samples using the new Illumina Trusight Tumor 170 solid tumor NGS panel.

"This partnership will provide a consistent approach to biomarker discovery and development from these valuable European clinical trial samples​," added Sloan.

The partnership is set to last for an "indefinite period of time," ​Sloan explained, and no further investment is required on Almac's part as the company has "significant​" capacity available. 

The services will be provided from Almac’s European facility in Craigavon, Northern Ireland.

The SPECTA infrastructure

Vassilis Golfinopoulos, EORTC Medical Director said the agreement with Almac is one of “several key partnership​” established to advance the SPECTA infrastructure.

The organization ultimately hopes to simplify patient inclusion in clinical trials of molecularly targeted treatment.

It is also looking to standardize Next Generation Sequencing (NGS) and Gene Expression Analysis in translational research projects in order to improve reproducibility and comparability of results.

(Feature image: iStock/manaemedia)

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars